Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Absorption, metabolism, and excretion of single dose oral [<sup>14</sup>C]camizestrant in healthy human female participants.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Identification, synthesis, and characterization of a unique N-glucuronide of an acid metabolite of camizestrant (AZD9833) in humans.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

A mismatch in enzyme-redox partnerships underlies divergent cytochrome P450 activities between human hepatocytes and microsomes.

Communications biology·2025
Same author

Hydrolysis of O-, N-, and N<sup>+</sup>-glucuronide metabolites in human feces.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

Physiologically Based Pharmacokinetic Modeling to Assess Perpetrator and Victim Cytochrome P450 2C Induction Risk.

Pharmaceutics·2025
Same author

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinalâ„¢).

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Dec 27, 2025

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.1K

Smallest Maximum Intramolecular Distance: A Novel Method to Mitigate Pregnane Xenobiotic Receptor Activation.

Michael J Bower1, Alex M Aronov1, Thomas Cleveland1

  • 1Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States.

Journal of Chemical Information and Modeling
|March 6, 2020
PubMed
Summary

A new molecular descriptor, the smallest maximum intramolecular distance (SMID), predicts pregnane xenobiotic receptor (PXR) activation. This finding helps reduce drug-drug interactions during pharmaceutical discovery and development.

More Related Videos

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Related Experiment Videos

Last Updated: Dec 27, 2025

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

13.1K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

8.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Area of Science:

  • Drug discovery and development
  • Medicinal chemistry
  • Pharmacology

Background:

  • Cytochrome P450 3A4 (CYP3A4) induction by pregnane xenobiotic receptor (PXR) activation is a significant challenge in drug development.
  • This induction can lead to detrimental drug-drug interactions, complicating therapeutic regimens.

Purpose of the Study:

  • To introduce a novel molecular descriptor, the smallest maximum intramolecular distance (SMID).
  • To establish the correlation between SMID and PXR activation.
  • To provide a method for utilizing SMID to guide medicinal chemists in modifying compounds to reduce PXR activation.

Main Methods:

  • Development and application of the smallest maximum intramolecular distance (SMID) descriptor.
  • Correlation analysis between SMID values and PXR activation levels.
  • Methodology for guiding lead compound modification based on SMID.

Main Results:

  • The smallest maximum intramolecular distance (SMID) was identified as a descriptor correlated with PXR activation.
  • A method was developed to leverage SMID for optimizing drug candidates.
  • This approach aims to decrease PXR activation and mitigate drug-drug interaction risks.

Conclusions:

  • SMID is a valuable descriptor for predicting and modulating PXR activation.
  • The developed method offers a strategy for rational drug design to minimize CYP3A4 induction.
  • This research contributes to safer and more effective pharmaceutical discovery.